[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Chrzanowska et al., 2022 - Google Patents

The effect of fatty acids on ciprofloxacin cytotoxic activity in prostate cancer cell lines—does lipid component enhance anticancer ciprofloxacin potential?

Chrzanowska et al., 2022

View HTML
Document ID
15884622862949635743
Author
Chrzanowska A
Olejarz W
Kubiak-Tomaszewska G
Ciechanowicz A
Struga M
Publication year
Publication venue
Cancers

External Links

Snippet

Simple Summary Most prostate cancers are initially hormone-dependent but later gain a hormone-independent phenotype associated with changes in lipid metabolism, including enhanced absorption of extracellular fatty acids. The aim of our study was to assess the …
Continue reading at www.mdpi.com (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48007—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the pharmacologically- or therapeutically-active agent being covalently bound or complexed to a modifying agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof

Similar Documents

Publication Publication Date Title
Han et al. Synergy between auranofin and celecoxib against colon cancer in vitro and in vivo through a novel redox-mediated mechanism
Wen et al. Pterostilbene suppresses ovarian cancer growth via induction of apoptosis and blockade of cell cycle progression involving inhibition of the STAT3 pathway
Li et al. Proteomic investigation of the sinulariolide-treated melanoma cells A375: Effects on the cell apoptosis through mitochondrial-related pathway and activation of caspase cascade
Crous-Masó et al. (−)-Epigallocatechin 3-gallate synthetic analogues inhibit fatty acid synthase and show anticancer activity in triple negative breast cancer
Xu et al. Effects of platycodin D on proliferation, apoptosis and PI3K/Akt signal pathway of human glioma U251 cells
Chen et al. Artesunate activates the intrinsic apoptosis of HCT116 cells through the suppression of fatty acid synthesis and the NF-κB pathway
Bonaccorsi et al. Synthesis of curcumin derivatives and analysis of their antitumor effects in triple negative breast cancer (TNBC) cell lines
Fratta Pasini et al. New insights into the role of ferroptosis in cardiovascular diseases
Yu et al. Physalis peruviana-derived physapruin A (PHA) inhibits breast cancer cell proliferation and induces oxidative-stress-mediated apoptosis and DNA damage
Chen et al. Breaking down leukemia walls: heteronemin, a sesterterpene derivative, induces apoptosis in leukemia Molt4 cells through oxidative stress, mitochondrial dysfunction and induction of talin expression
Labbozzetta et al. Phytol and heptacosane are possible tools to overcome multidrug resistance in an in vitro model of acute myeloid leukemia
Chrzanowska et al. The effect of fatty acids on ciprofloxacin cytotoxic activity in prostate cancer cell lines—does lipid component enhance anticancer ciprofloxacin potential?
Scicchitano et al. The double-edged sword of oleuropein in ovarian cancer cells: From antioxidant functions to cytotoxic effects
Fan et al. α-Linolenic acid suppresses proliferation and invasion in osteosarcoma cells via inhibiting fatty acid synthase
Di Giacomo et al. Role of caryophyllane sesquiterpenes in the entourage effect of Felina 32 hemp inflorescence phytocomplex in triple negative MDA-MB-468 breast cancer cells
Yun et al. Acacetin inhibits the growth of STAT3-activated DU145 prostate cancer cells by directly binding to signal transducer and activator of transcription 3 (STAT3)
Lee et al. Sphingosine kinase-1 involves the inhibitory action of HIF-1α by chlorogenic acid in hypoxic DU145 cells
Nkwe et al. Anticancer mechanisms of bioactive compounds from Solanaceae: An update
Elhady et al. Anticancer effects of new ceramides isolated from the Red Sea Red Algae Hypnea musciformis in a model of Ehrlich Ascites carcinoma: LC-HRMS analysis profile and molecular modeling
Shih et al. Tackling the cytotoxic effect of a marine polycyclic quinone-type metabolite: Halenaquinone induces molt 4 cells apoptosis via oxidative stress combined with the inhibition of HDAC and topoisomerase activities
Zhang et al. Glycycoumarin sensitizes liver cancer cells to ABT-737 by targeting de novo lipogenesis and TOPK-survivin axis
Gallorini et al. The selective acetamidine-based iNOS inhibitor CM544 reduces glioma cell proliferation by enhancing PARP-1 cleavage in vitro
Gao et al. Synthetic tryptanthrin derivatives induce cell cycle arrest and apoptosis via akt and MAPKs in human hepatocellular carcinoma cells
Xu et al. ELOVL5-mediated long chain fatty acid elongation contributes to enzalutamide resistance of prostate cancer
Park et al. The Antiproliferative activity of oxypeucedanin via induction of G2/M phase cell cycle arrest and p53-dependent MDM2/p21 expression in human hepatoma cells